xintela

Q4 2021

4.8 milion SEK granted from Vinnova

The grant partly finances the clinical study with XSTEM on patients with difficult-to-heal leg ulcers.

New patent approvals of Xintela's stem cell products

The patent, which has previously been granted in Europe, is now granted also in Israel, Mexico and South Africa, and we expect several approvals from other countries in 2022.

Dividend of Targinta shares to Xintela's shareholders

At the Extraordinary General Meeting on January 17, it was decided that Targinta will be spun out and that the Targinta shares will be made available for trading shortly afterward. In the spin-out, Xintela's shareholders will receive shares in Targinta in proportion to their share-holding in Xintela.

Summary of the interim report

The "Company" or "Xintela" refers to Xintela AB (publ), corporate registration number 556780-3480.

Fourth quarter October 1 – December 31, 2021

- Income amounted to TSEK 0 (0).
- Loss before tax totalled TSEK 26,643 (loss: 25,335).
- Loss per share* was SEK 0.30 (loss: 0.34).
- At December 31, 2021, the equity/assets ratio** was 16% (57).

The period January 1 – December 31, 2021

- Income amounted to TSEK 0 (0).
- Loss before tax totalled TSEK 58,394 (loss: 50,257).
- Loss per share* was SEK 0.65 (loss: 0.68).

** Earnings/loss per share: Profit/loss for the period divided by 89,134,021 shares, which was the number of registered shares at December 31, 2021. In the year-earlier period, the Company had 73,966,564 registered shares.*

*** Equity/assets ratio: Equity divided by total capital.*

Amounts in parentheses: Comparative period of the preceding year.

Significant events in the fourth quarter of 2021

- Targinta selects lead drug candidate for triple-negative breast cancer. (October 15, 2021)
- Xintela taking EQSTEM, a stem cell product for horses, towards the market. (October 27, 2021)
- New board of directors appointed in Targinta AB. (October 29, 2021)
- Update on status and strategi for Xintela and Targinta. (November 4, 2021)
- Xintela receives a loan of SEK 9 million. (November 18, 2021)
- Xintela AB Interim report January - September 2021. (November 19, 2021)
- Xintela and ScanVet Animal Health A/S sign Letter of Intent. (December 13, 2021)
- Notice of extraordinary general meeting in Xintela AB (publ). (December 28, 2021)

Significant events after the end of the period

- Bulletin from the extraordinary general meeting in Xintela. (January 17, 2022)
- Xintela granted 4.8 million SEK from Vinnova. (January 18, 2022)

CEO comments

In Focus: Clinical studies and Targinta spin-out

Our oncology pipeline and Targinta subsidiary have evolved from scientific concept to a full-blown drug development company with a unique proprietary oncology target, with function-blocking and toxin-armed antibodies that show effect in preclinical models for aggressive cancer, and with a patent portfolio that protects both the target and the pipeline. At the Extraordinary General Meeting on January 17, it was decided that Targinta will be spun out before Xintela's Annual General Meeting and that the Targinta shares will be made available for trading shortly afterward. In the spin-out, Xintela's shareholders will receive shares in Targinta in proportion to their shareholding in Xintela and will thus have the opportunity to participate in Targinta's exciting onward journey. We now look forward to Targinta´s venture as an independent drug development company, developing novel therapeutic options for patients affected by aggressive and deadly cancers which today lack effective treatment.

Targinta has recently designated the function-blocking antibody TARG10 as candidate drug for the treatment of triple-negative breast cancer, which is one of the company's focus indications. Targinta thus takes the step from preclinical research into preclinical development to prepare TARG10 for future clinical trials.

Targinta is also developing antibodies armed with a powerful toxin, known as Antibody Drug Conjugates (ADC), and plans to select the first ADC drug candidate this quarter for the treatment of aggressive cancers including glioblastoma.

Xintela will now focus entirely on the development of stem cell-based therapies. The stem cell product XSTEM will enter clinical testing for the first time in humans in two different phase I/IIa clinical studies, one for knee osteoarthritis and the other for difficult-to-heal leg ulcers. The main goal of the studies is to show that XSTEM is safe but also to obtain preliminary efficacy results.

The osteoarthritis study is awaiting its final approval from the regulatory authority in Australia, which is expected within the next few weeks. Patients with knee osteoarthritis will receive a single injection of XSTEM into the knee joint and will then be followed for 18 months, with safety and efficacy evaluations every six months. We expect to have initial safety data before the end of the year and efficacy readout during 2023. Our preclinical studies have shown that XSTEM has a regenerative effect and therefore has the potential to be a breakthrough treatment for osteoarthritis.

The second study, evaluating XSTEM for the treatment of difficult-to-heal (chronic) leg ulcers, is scheduled to start mid this year. In January, we were pleased to receive a grant from Vinnova of SEK 4.8 million, to carry out the clinical study in collaboration with Professor Folke Sjöberg and his colleagues at Linköping University Hospital. We are now working to complete the clinical documentation for an application to the Medical Products Agency, which we plan to submit in March. In the study, XSTEM will be applied to the wound to assess safety and wound-healing effect over 10 weeks, and we expect results already this year. Upon positive results, we plan to broaden XSTEM's use for the treatment of burns and other skin defects.

We also plan a clinical study in horses with the stem cell product EQSTEM for the treatment of joint disease. In December, we signed a Letter of Intent with the Danish veterinary company ScanVet Animal Health and have ongoing activities in the joint clinical and commercial development of EQSTEM. One major advantage of a veterinary stem cell product is its shorter development time, meaning it can reach the market and generate revenue significantly sooner than the equivalent for humans.

Our stem cell patent portfolio, which protects the development and commercialization of our stem cell products for all therapeutic uses, continues to broaden its geographic reach. It has previously been approved in Europe, and is now approved also in Israel, Mexico, and South Africa, and we expect several approvals from other countries in 2022.

Xintela's focus on clinical studies for stem cell therapies and Targinta's focus on preclinical development of therapeutic antibodies for aggressive cancers, mean a continued need to find the resources required to perform the value increasing development before partnership and outlicensing and thus generate value for our shareholders. We focus on securing our financing needs and are currently evaluating several financing possibilities, including development collaborations, project financing, equity capital raisies, grants and loans.

Evy Lundgren-Åkerlund
CEO, Xintela AB (publ)

Xintela's operations

Xintela develops stem cell-based treatments with a focus on osteoarthritis and difficult-to-heal leg ulcers and, through the wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancer such as triple-negative breast cancer and the brain tumor glioblastoma. The business is focused on diseases where there is a high medical need and effective treatments are lacking today.

STEM CELL-BASED THERAPIES

Stem cell product XSTEM®

Xintela uses its proprietary stem cell marker, integrin α10β1, to select and quality assure stem cell products from donated adipose tissue from healthy individuals. XSTEM is patented both as a product and for therapeutic use in all indications. This gives Xintela the best conditions to develop safe and effective stem cell-based treatments for a variety of diseases.

Clinical study with XSTEM for the treatment of osteoarthritis

Xintela's first clinical study (Phase I/IIa), will be conducted in Australia in patients with moderate knee osteoarthritis (grade II-III) and the study is estimated to start during Q1 2022. The primary goal is to show that XSTEM is safe, but also to obtain preliminary results showing that the product has DMOAD (Disease Modifying Osteoarthritis Drug) properties and can slow down cartilage and joint degradation as well as regenerate damaged cartilage and thus improve joint function. Three different doses will be assessed in up to 54 patients and each patient will be followed for 18 months with continuous safety evaluation and preliminary efficacy evaluation every six months. Xintela's preclinical results strongly support DMOAD effect of XSTEM.

Clinical study with XSTEM for the treatment of difficult-to-heal leg ulcers

Xintela's second clinical study (Phase I/IIa), in patients with difficult-to-heal leg ulcers, is scheduled to start in mid-2022. The study will be carried out in collaboration with Professor Folke Sjöberg and his team at University Hospital in Linköping. XSTEM will be administrated topically to the ulcers and patients will then be followed over a period of 10 weeks to evaluate safety and also preliminary effect.

Stem cell product EQSTEM® for osteoarthritis in horses

Xintela has developed the stem cell product EQSTEM for the treatment of horses. Positive results from two preclinical osteoarthritis studies in horses have shown strong support for the continued development of EQSTEM for treatment of osteoarthritis and other degenerative joint diseases in horses. Xintela plans to take EQSTEM to market in collaboration with the University of Copenhagen and commercial players in veterinary medicine.

In-house production of stem cells

Xintela's stem cell products are produced in its GMP-approved facility, which significantly reduces both production costs and

Osteoarthritis (OA)
Osteoarthritis (OA) is a debilitating and painful joint disease characterised by cartilage and joint degradation and loss of chondrocyte function. It is the most common chronic disease of the joints, mainly in the knee, hip and hand, and the single most common cause of disability in older adults. It is estimated to affect about 25 percent of all individuals over 60 years of age and is on the rise due to an increasing ageing population. Pharmacological treatments offered today only provide symtomatic relief but do not treat the cause of the cartilage degradation.

Difficult-to-heal leg ulcers
Difficult-to-heal leg ulcers, including venous leg ulcers, represent a major clinical problem, both in terms of suffering and pain for the patient, as well as to healthcare due to the huge financial burden for treatment costs. It is estimated that between 0.18 and 1 percent of the population is affected by venous leg ulcers. The prevalence increases with age and is estimated to 4 percent in individuals above 65 years. Current treatments of difficult-to-heal leg ulcers include compression therapy and surgery, but there are no efficient pharmacological treatments available.

risks of delays. In addition to producing XSTEM for in-house development, Xintela's strategy is to become an established manufacturer of the Company's stem cell products developed together with partners. In longer term, Xintela's GMP facility and production operations may also be used for contract manufacturing in the development and commercialisation of other ATMP products.

Commercialisation strategy for stem cell products
The company's strategy is to develop the company's stem cell products to a point where they can be attributed to a clear increase in value, then enter into partnerships and licensing deals. For XSTEM, that point is after safety readout and Proof-of-Concept in humans, ie after clinical Phase I/IIa and for EQSTEM after Proof-of-Concept in horse patients. Xintela is active in partnering discussions and has built up a large network of potential licensees in the pharmaceutical industry.

ANTIBODY-BASED CANCER THERAPIES

Therapeutic antibodies directed against the target integrin α10β1
Xintela's subisidiary Targinta, develops therapeutic antibodies specifically binding to the novel cancer target integrin α10β1. The candidate drugs are being developed for the treatment of aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma. Targinta develops two different types of antibodies: function-blocking antibodies that can inhibit critical cancer cell functions such as proliferation and migration, as well as antibody-drug conjugates (ADCs), that have a cytotoxin linked to the antibody that kills cancer cells. The company has previously reported inhibitory effect of antibodies on the proliferation and migration of cancer cells as well as reduced tumor growth in preclinical models.

Targinta has a patent portfolio that protects both the cancer target integrin α10β1 and the antibodies themselves and thus can prevent competitors from developing integrin α10β1 antibodies for the treatment of aggressive cancers.

Selecting antibody candidate drug
Targinta has recently selected the first function-blocking drug candidate, TARG10, for the treatment of triple-negative breast cancer. TARG10 has shown inhibitory effects on both tumor growth and tumor migration in models for triple-negative breast cancer and preclinical development of the antibody has now been initiated in preparation for future clinical studies. Targinta plans to select the next candidate drug for the treatment of aggressive cancer during the first quarter of 2022 and where the antibody is an ADC (antibody-drug conjugate).

Targinta's commercialisation strategy
Targinta's strategy is to enter into commercial agreements already after preclinical development. Drug candidates directed to new targets on cancer cells, known as First-in-Class products, are very attractive to drug development companies due to the high need for new and more effective cancer treatments. Licensing deals with First-in-Class assets are frequently entered into at the preclinical stage.

Targinta spin-out
Xintela's extraordinary general meeting on January 17, 2022, decided to dividend the Targinta shares in accordance with the Lex Asea rules, where Xintela's shareholders will receive shares in Targinta in proportion to their shareholding in Xintela. The dividend will be carried out before Xintela's annual general meeting and listing of the Targinta shares will take place shortly thereafter.

Triple-negative breast cancer (TNBC)
TNBC is an aggressive form of breast cancer with high risk of recurrence and metastasis. It is diagnosed in about 300,000 patients globally per year, and the 5-year survival of TNBC is about 12 percent.

Glioblastoma
Glioblastoma is the most common and most aggressive form of brain tumor in adults. About 30,000 individuals are diagnosed with glioblastoma in the US and EU each year, and the 5-year survival is only about 3 percent.

Xintela's development projects

Xintela develops medical products within stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 found on mesenchymal stem cells and on some aggressive cancer cells.

In stem cell therapy, integrin α10β1 is used to select and quality assure stem cells in the proprietary stem cell products XSTEM® for the treatment of humans, and EQSTEM® for the treatment of horses. The company will initiate clinical studies for the treatment of osteoarthritis and difficult-to-heal leg ulcers. The strategy is to further develop ARDS (Acute Respiratory Distress Syndrome) in collaboration with a partner.

In cancer therapy, therapeutic antibodies are developed that specifically bind to the new target on cancer cells, integrin α10β1, for the treatment of aggressive cancers such as triple-negative breast cancer and brain tumor glioblastoma.

Stem cell-based therapies



Antibody-based cancer therapies



Financial reports

Condensed statement of comprehensive income for the Company

Income
The Company reported net sales of TSEK 0 (0) for the forth quarter of the year. Other income totalled TSEK 2,551 (4,865) and pertained to costs of TSEK 2,519 (4,865) for the oncology business that were invoiced onward to the subsidiary Targinta and grants of TSEK 32 (0) from Vinnova.

Earnings
Loss for the period was TSEK 12,120 (loss: 11,178).

Research and development costs, which account for the highest portion of the Company's costs, amounted to TSEK 11,529 (12,658) for the October - December period.

Marketing and sales costs amounted to TSEK 1,357 (1,052) for the quarter.

Administrative expenses amounted to TSEK 1,788 (2,333) for the period.

For the October-December 2021 period, loss before tax was TSEK 26,643 (loss: 25,335).

	Quarter 4		Full year	
(TSEK)	10/1/2021 12/31/2021	10/1/2020 12/31/2020	1/1/2021 12/31/2021	1/1/2020 12/31/2020
Operating income				
Net sales	-	-	-	-
Cost of goods sold	-	-	-	-
Gross profit	-	-	-	-
Operating expenses				
Research and development costs	-11,529	-8,894	-44,120	-38,170
Selling costs	-1,354	-1,086	-4,095	-3,757
Administrative expenses	-1,788	-1,847	-6,773	-6,917
Other operating income	2,551	4,764	11,433	14,947
Other operating expenses	-	-	-	-
Operating loss	**-12,120**	**-7,063**	**-43,556**	**-33,897**
Profit/loss from financial items				
Financial income	-	-	-	-
Financial expenses	-223	-1,253	-538	-2,667
Loss before tax	**-12,343**	**-8,315**	**-44,094**	**-36,564**
Appropriations	-14,300	-	-14,300	-13,693
Tax on loss for the year	0	-	-	-
Loss for the period	**-26,643**	**-8,315**	**-58,394**	**-50,257**
Loss per share, SEK	-0.30	-0.14	-0.65	-0.68

Condensed balance sheet for the Company

ASSETS

Financial position
On 31 December 2021, Xintela's equity/assets ratio was 16 per cent (57) and equity amounted to TSEK 3,947 (27,607). The Company's cash and cash equivalents amounted to TSEK 9,941 (33,601). On 31 December 2021, the Company's total assets amounted to TSEK 24,742 (48,513).

(TSEK)	12/31/2021	12/31/2020
ASSETS		
Fixed assets		
Intangible assets	746	1,050
Tangible assets	7,012	8,877
Financial assets	18	71
Participations in subsidiaries	839	839
Total fixed assets	**8,615**	**10,838**
Current assets		
Receivables from subsidiaries	3,081	3,476
Tax assets	706	-
Other receivables	1,449	-
Prepaid expenses	950	598
Cash and cash equivalents	9,941	33,601
Total current assets	**16,127**	**37,675**
TOTAL ASSETS	**24,742**	**48,513**

Condensed balance sheet for the Company

EQUITY AND LIABILITIES

(TSEK)	12/31/2021	12/31/2020
EQUITY AND LIABILITIES		
Equity		
Share capital	2,674	2,219
Development expenses fund	0	113
Share premium reserve	242,714	208,435
Retained earnings	-183,047	-132,903
Loss for the period	-58,394	-50,257
Total equity	**3,947**	**27,607**
Current liabilities		
Accounts payable	3,899	2,712
Tax liability	135	233
Other liabilities	13,019	13,646
Accrued expenses and deferred income	3,742	4,316
Total current liabilities	**20,795**	**20,907**
TOTAL EQUITY AND LIABILITIES	**24,742**	**48,513**

Condensed cash flow statement for the Company

Cash flow and investments

Xintela's cash flow for the October - December 2021 period was TSEK -5,953 (20,572). Investments amounted to TSEK 525 (0). The Company's investments in tangible assets were linked to the establishment of Xintela's own GMP facility for the manufacture of stem cells for clinical trials.

	Quarter 4		Full year	
(TSEK)	10/1/2021 12/31/2021	10/1/2020 12/31/2020	1/1/2021 12/31/2021	1/1/2020 12/31/2020
Operating activities				
Operating loss	-12,120	-11,178	-43,556	-33,897
Depreciation/amortisation	826	1,002	3,425	3,569
Financial income		-		-
Financial expenses	-223	-464	-538	-2,667
Cash flow from operating activities before changes in working capital	**-11,517**	**-10,640**	**-40,669**	**-32,995**
Changes in working capital				
Increase/decrease in receivables	8,505	7,199	-2,111	-1,471
Increase/decrease in current liabilities	11,870	1,835	-112	13,137
Changes in working capital	**20,375**	**9,034**	**-2,223**	**11,666**
Cash flow from operating activities	**8,858**	**-1,606**	**-42,892**	**-21,330**
Investing activities				
Increase/decrease of tangible assets	-525	-	-1,255	-383
Increase/decrease of intangible assets		-		-
Increase/decrease of financial assets	14	27	53	54
Cash flow from investing activities	**-511**	**27**	**-1,202**	**-329**
Financing activities				
New share issue		35,844	34,734	32,697
New share issue, warrants		-		35,844
Group contribution paid	-14,300	-13,693	-14,300	-13,693
Increase / decrease of long-term liabilities		-		-
Cash flow from financing activities	**-14,300**	**22,151**	**20,434**	**54,848**
Change in cash and cash equivalents	-5,953	20,572	-23,660	33,189
Cash and cash equivalents at the beginning of the period	15,894	13,029	33,601	412
Cash and cash equivalents at the end of the period	**9,941**	**33,601**	**9,941**	**33,601**

Statement of changes in equity for the Company

(TSEK)	Share capital	Development expenses	Share premium	Retained earnings	Loss for the period	Total
Opening balance, January 1, 2020	**1,224**	**245**	**140,889**	**-89,504**	**-43,530**	**9,323**
Reversal of prior year's accruals	-	-	-	-43,530	43,530	-
Development expenses fund	-	-132	-	132	-	-
New share issue	502		32,195	-	-	32,697
New share issue, warrants	493	-	35,351	-	-	35,844
Loss for the period	-	-	-	-	-50,257	-50,257
Equity, December 31, 2020	**2,219**	**113**	**208,435**	**-132,903**	**-50,257**	**27,607**
Opening balance, January 1, 2021	**2,219**	**113**	**208,435**	**-132,903**	**-50,257**	**27,607**
Reversal of prior year's accruals	-	-	-	-50,257	50,257	0
Development expenses fund	-	-113	-	113	-	0
New share issue, offset	96	-	8,500	-	-	8,596
New share issue	359		25,779			26,138
Loss for the period	-	-	-	-	-58,394	-58,394
Equity, December 31, 2021	**2,674**	**0**	**242,714**	**-183,047**	**-58,394**	**3,947**

Declaration by the Board of Directors and the CEO

Gregory Batcheller

Maarten de Château

Lars Hedbys

Sven Kili

Karin Wingstrand

Evy Lundgren-Åkerlund

The Board of Directors and the Chief Executive Officer certify that the interim report provides a true and fair view of the company's business, financial position, performance and describes material risks and uncertainties, to which the company is exposed.

The interim report has not been reviewed by the company's auditors.

Lund February 25, 2022

Gregory Batcheller
Chairman

Maarten de Château
Board member

Lars Hedbys
Board member

Sven Kili
Board member

Karin Wingstrand
Board member

Evy Lundgren-Åkerlund
CEO

Other information

The share
Xintela AB (publ) was listed on Nasdaq First North Growth Market in Stockholm on 22 March 2016 under the ticker symbol "XINT." First North Growth Market is an alternative marketplace, operated by an exchange within the NASDAQ OMX Group. Companies on First North Growth Market are not subject to the same rules as companies on the regulated main market. They are subject to a less regulated framework, adapted for small growth companies. A company listed on First North Growth Market may therefore entail a higher investment risk than a company listed on the main market. All companies listed on First North Growth Market have a Certified Adviser to oversee their compliance with the rules. The exchange assesses applications for admission to trading. Xintela's Certified Adviser on Nasdaq First North Growth Market is Erik Penser Bank AB, +46 (0)8 463 80 00, certifiedadviser@penser.se.

At 31 December 2021, the number of shares was 89,134,021. The Company has only one class of shares. Each share carries identical rights to the Company's assets and earnings, and one vote at General Meetings.

	Jan - Dec 2021	Jan - Dec 2020
No. of shares before full dilution	89,134,021	73,966,564
No. of shares after full dilution	89,134,021	73,966,564
Loss per share before full dilution	-0.65	-0.68
Average no. of shares before full dilution	82,867,900	48,542,340
Average no. of shares after full dilution	82,867,900	48,542,340

Financial statements in accordance with K3
This report has been prepared in accordance with BFNAR 2012: 1 Annual Report and Consolidated Financial Statements (Q3) and the accounting principles are unchanged compared with those applied in the Annual Report for 2020. For complete accounting principles, see the Annual Report 2020.

Review by auditors
This year-end report has not been reviewed by the Company's auditor.

Financial calendar
Interim report Q1 2022: May 20, 2022
Annual report 2021: April 22, 2022
Interim report Q2 2022: August 26, 2022
Interim report Q3 2022: November 25, 2022

Annual General Meeting and availability of the annual report
The Annual General Meeting will be held in Lund on May 6, 2022. The annual report will be available for download on the Company's website (www.xintela.se) no later than April 22, 2022.

Proposal for disposition of Xintela's results
The Board of Directors and the President propose that no share dividend be paid for the financial year 2021.

Risks and uncertainties
Limited resources
Xintela is a small company with limited resources in terms of management, administration, and capital. The implementation of any major strategies requires optimization of the Company's resource appropriation. There is a risk that the Company's resources could be insufficient, and lead to financial and operational problems. The company's ability to continue its operations depends on the ongoing work with the company's financing being successful. Focused work is underway to secure the company's future financing and the Board's assessment is that we will successfully secure future financing needs.

Dependence on key individuals and employees
Xintela's success is based on the knowledge, experience, and creativity of a few specific individuals. The Company's future is dependent on being able to recruit qualified employees. The Company works hard to reduce this dependency by maintaining proper documentation of procedures and working methods.

Earning capacity and capital requirements
Drug development is both expensive and time-consuming. It may take longer than expected before the Company can generate a positive cash flow. To cover these costs, Xintela may need to raise new capital. There is no guarantee that such capital can be obtained on terms that are favorable to shareholders. Failure to generate sufficient profits may impact the Company's market value.

Sales risk
There is no certainty that the products developed by the Company will gain the market acceptance reflected in this interim report. The quantity of products sold may be lower, and the period required for market establishment may be longer, than the Company currently has reason to believe.

Xintela in brief

Xintela develops medical products within stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1, which is found on mesenchymal stem cells and on certain aggressive cancer cells.

In stem cell therapy, integrin α10β1 is used to select and quality-assure stem cells in the manufacturing of the patented stem cell product XSTEM®, which is now entering a clinical development phase. The first clinical study with XSTEM (Phase I/IIa), for the treatment of knee osteoarthritis, is scheduled to start in Q1 2022. The next clinical study with XSTEM for treatment of difficult-to-heal leg ulcers is scheduled to start in mid-2022. The primary goal with the clinical studies is safety but also to obtain preliminary results showing regenerative properties of XSTEM. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In parallel, Xintela is preparing for clinical development of a veterinary stem cell product for osteoarthritis in horses and is evaluating other future indications for XSTEM, including the lung complication ARDS (Acute Respiratory Distress Syndrome). Xintela has conducted preclinical studies in relevant animal models which provide strong support for XSTEM as a safe and effective stem cell treatment.

In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, targeted antibody-based treatments (first-in-class) are developed for treatment of aggressive cancer such as triple-negative breast cancer and the brain tumor glioblastoma. The company's targeting antibodies are directed against the novel marker integrin α10β1, which is highly expressed in these cancers. Results from preclinical models have shown that the antibodies have an inhibitory effect on both tumor growth and migration of cancercells. The first drug candidate, TARG10, has entered preclinical development phase with the aim of building a strong regulatory package for future clinical studies in cancer patients.

Xintela operates at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm.